Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Stanford University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07479550CT.gov Study of Psilocybin Under Anesthesia Controlled by EEG | — | Not Yet Recruiting | — | — | — |
NCT07251491CT.gov Psilocybin to Treat Depression in Spinal Cord Injury | — | Recruiting | — | — | — |
NCT07490353CT.gov Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects | — | Recruiting | — | — | — |
NCT03923361CT.gov Neural and Antidepressant Effects of Propofol (Phase 2) | — | Withdrawn | — | — | — |
NCT02935647CT.gov Burst Suppression Anesthesia for Treatment of Severe Depression | — | Completed | — | — | — |
NCT01935115CT.gov Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Propofol (this asset) | Stanford University | Approved | BB · 66 |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| 17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL | Massachusetts General Hospital | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Propofol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Headache Disorder | — | P4 | BBB · 73 |
| Morbid Obesity | — | P4 | BBB · 73 |
| Alzheimer Disease | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Propofol in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/propofol-major-depressive-disorder-23000
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →